KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Dividends payables (2016 - 2025)

Abbott Laboratories' Dividends payables history spans 17 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Dividends payables rose 7.13% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 7.13%, while the annual FY2025 figure was $1.1 billion, 7.13% up from the prior year.
  • Dividends payables for Q4 2025 was $1.1 billion at Abbott Laboratories, up from $1.0 billion in the prior quarter.
  • Across five years, Dividends payables topped out at $1.1 billion in Q4 2025 and bottomed at $797.0 million in Q3 2021.
  • The 5-year median for Dividends payables is $887.5 million (2022), against an average of $914.2 million.
  • The largest annual shift saw Dividends payables rose 25.75% in 2021 before it rose 2.87% in 2022.
  • A 5-year view of Dividends payables shows it stood at $831.0 million in 2021, then increased by 6.74% to $887.0 million in 2022, then rose by 7.67% to $955.0 million in 2023, then rose by 7.23% to $1.0 billion in 2024, then increased by 7.13% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Dividends payables are $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).